01033nas a2200373   4500000000100000000000100001000000100002008004100003653001100044653002600055653002500081653003100106653004200137653001700179653001500196653002000211653000900231100001500240700001500255700001200270700001300282700001500295700001300310700001500323700001400338700001500352700001400367700001400381245020300395250001500598300000800613490000700621020003100628       2023                            d10aHumans10aRetrospective Studies10aEngland/epidemiology10a*Nebulizers and Vaporizers10achronic obstructive pulmonary disease10aExacerbation10aFf/umec/vi10aHealthcare cost10aSitt1 aA. Ismaila1 aK. Rothnie1 aR. Wood1 aV. Banks1 aL. Camidge1 aA. Czira1 aC. Compton1 aR. Sharma1 aS. Millard1 aO. Massey1 aD. Halpin00aBenefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study  a2023/09/26  a2290 v24  a1465-9921 (Print)1465-9921